David R. Taft
Professor of Pharmaceutics
B.S. (Pharmacy), University of Rhode IslandPh.D., University of Connecticut
david.taft@liu.edu
Description
David R. Taft is Professor of Pharmaceutics of the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University (LIU Pharmacy). He received his undergraduate degree in Pharmacy from the University of Rhode Island and his Ph.D. in Pharmaceutical Science from the University of Connecticut. He joined the faculty of Long Island University after completing a post-doctoral fellowship at the University of North Carolina School of Pharmacy.
Professor Taft has served on the faculty of LIU Pharmacy for over two decades. His research interests are in the area of pharmacokinetics with a focus on drug disposition mechanisms, and he has collaborated with numerous pharmaceutical companies on preclinical evaluation of novel therapeutic entities. He has published more than 100 manuscripts, research abstracts and book chapters, and he co-edited two books. He serves on the editorial advisory boards of Journal of Pharmaceutical Sciences and Drug Development and Industrial Pharmacy. Dr. Taft is a past recipient of the American Association of Pharmaceutical Scientists (AAPS) New Investigator Grant in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, and the University of Connecticut School of Pharmacy Distinguished Alumnus Award.
Specialties
Pharmacokinetics and Drug Disposition; Pharmaceutics
Research Interests:
- Pharmacokinetic evaluation of novel anticancer compounds
- Pharmaceutical formulation development and evaluation.
- Pharmacokinetic modeling and simulation
Preclinical drug disposition studies – in vitro and in vivo.
Publications
Rami S. Komrokji, Azra Raza, Jeffrey E. Lancet, Chen Ren, David Taft, Manoj Maniar, Francois Wilhelm and Alan F, “Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndrome.”, British Journal of Haematology 162:517-254, 2013.
Takao Ohnuma, Deborah Lehrer, Chen Ren, Sool Yeon Cho, Manoj Maniar, Lewis Silverman, Max Sung1 Herbert F Gretz III, Vladimir Benisovich, Shyamala Navada, Eugene Akahoho, Eric Wilck, David R. Taft, John Roboz, Francois Wilhelm, and James F Holland., “Phase 1 Study of Intravenous Rigosertib (ON 01910.Na), a Novel Benzyl Styryl Sulfone Structure Producing G2/M Arrest and Apoptosis, in Adult Patients with Advanced Cancer”, American Journal of Cancer Research 3:323-338, 2013.
Michael P. White, Mariana Babayeva, David R. Taft, and Manoj Maniar, “Determination of Intestinal Permeability of Rigosertib (ON 01910.Na, Estybon™): Correlation with Systemic Exposure”, Journal of Pharmacy and Pharmacology 65:960-969, 2013.
Mitalee Tamhane, Manoj Maniar, Chen Ren, Kenza E. Benzeroual and David R. Taft., “Disposition Of ON 01210.Na (Ex-RAD®), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure”, Journal of Pharmaceutical Sciences 102:732–740, 2013.
Shubhankar Suman, Kamal Datta, Kathryn Doironi, Chen Ren, Ramesh Kumar, David R. Taft, Albert J. Fornace Jr. and Manoj Maniar., “Radioprotective Effects of ON 01210.Na upon Oral Administration.”, Journal of Radiation Research 53:368-376, 2012.
Horatio Priestap, Maria Torres, Robert Rieger, Kathleen Dickman, Tomoko Freshwater, David R. Taft, Manuel Barbieri and Charles Iden, “Aristolochic Acid I Metabolism in the Isolated Perfused Rat Kidney”, Chemical Research in Toxicology 25:130-139, 2012.
Mariana Babayeva, Susan Cox, Michael P. White, and David R. Taft, “Renal Excretion Of Apricitabine in Rats: Ex Vivo and In Vivo Studies.”, European Journal of Drug Metabolism and Pharmacokinetics 36(3):141-150, 2011.
David R. Taft, Rutesh Dave, Amanda M. Gillum and Manoj Maniar, “ON 01910.Na (Estybon®, Rigosertib)”, Drugs of the Future, 36(6):433-440, 2011.
Amy W. Chun, Robert E. Freshwater,
David R. Taft, Amanda M. Gillum and Manoj Maniar, “The Effect of Formulation and Route of Administration on the Systemic Availability of Ex-RADä, a New Radioprotectant, in Preclinical Species”, Biopharmaceutics and Drug Disposition 32(2):99-111, 2011.
Lectures and Presentations
Rami S. Komrokji, Azra Raza, Jeffrey E. Lancet, Chen Ren, David Taft, Manoj Maniar, Francois Wilhelm and Alan F, “Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndrome.”, British Journal of Haematology 162:517-254, 2013.
Takao Ohnuma, Deborah Lehrer, Chen Ren, Sool Yeon Cho, Manoj Maniar, Lewis Silverman, Max Sung1 Herbert F Gretz III, Vladimir Benisovich, Shyamala Navada, Eugene Akahoho, Eric Wilck, David R. Taft, John Roboz, Francois Wilhelm, and James F Holland., “Phase 1 Study of Intravenous Rigosertib (ON 01910.Na), a Novel Benzyl Styryl Sulfone Structure Producing G2/M Arrest and Apoptosis, in Adult Patients with Advanced Cancer”, American Journal of Cancer Research 3:323-338, 2013.
Michael P. White, Mariana Babayeva, David R. Taft, and Manoj Maniar, “Determination of Intestinal Permeability of Rigosertib (ON 01910.Na, Estybon™): Correlation with Systemic Exposure”, Journal of Pharmacy and Pharmacology 65:960-969, 2013.
Mitalee Tamhane, Manoj Maniar, Chen Ren, Kenza E. Benzeroual and David R. Taft., “Disposition Of ON 01210.Na (Ex-RAD®), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure”, Journal of Pharmaceutical Sciences 102:732–740, 2013.
Shubhankar Suman, Kamal Datta, Kathryn Doironi, Chen Ren, Ramesh Kumar, David R. Taft, Albert J. Fornace Jr. and Manoj Maniar., “Radioprotective Effects of ON 01210.Na upon Oral Administration.”, Journal of Radiation Research 53:368-376, 2012.
Horatio Priestap, Maria Torres, Robert Rieger, Kathleen Dickman, Tomoko Freshwater, David R. Taft, Manuel Barbieri and Charles Iden, “Aristolochic Acid I Metabolism in the Isolated Perfused Rat Kidney”, Chemical Research in Toxicology 25:130-139, 2012.
Mariana Babayeva, Susan Cox, Michael P. White, and David R. Taft, “Renal Excretion Of Apricitabine in Rats: Ex Vivo and In Vivo Studies.”, European Journal of Drug Metabolism and Pharmacokinetics 36(3):141-150, 2011.
David R. Taft, Rutesh Dave, Amanda M. Gillum and Manoj Maniar, “ON 01910.Na (Estybon®, Rigosertib)”, Drugs of the Future, 36(6):433-440, 2011.
Amy W. Chun, Robert E. Freshwater,
David R. Taft, Amanda M. Gillum and Manoj Maniar, “The Effect of Formulation and Route of Administration on the Systemic Availability of Ex-RADä, a New Radioprotectant, in Preclinical Species”, Biopharmaceutics and Drug Disposition 32(2):99-111, 2011.
Books/Chapters
Mark C. Rogge and David R. Taft (Eds), Preclinical Drug Development, Second Edition, New York, Informa Heathcare, 2009.
Robert O. Williams III, David R. Taft and Jason T. McConville (Eds), Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, New York, Informa Heathcare, 2007.
Mark C. Rogge and David R. Taft (Eds), Preclinical Drug Development, New York, Informa Heathcare, 2005.
Grants/Contracts
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $48,954 2015.
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $49,231, 2014.
Onconova Therapeutics Inc, “Preclinical Studies with Novel Therapeutic Compounds”, $35,585, 2013.
TPP Global Development, “Preclinical Studies with Novel Compounds”, $9,000, 2013.
Parion Sciences, Inc, “Renal Excretion of Parion ENaC blockers in the Isolated Perfused Rat Kidney”, $25,684, 2011.
Honors/Awards
University of Connecticut School of Pharmacy Distinguished Alumnus Award, 2011
American Association of Colleges of Pharmacy Academic Leadership Fellow, 2004-2005
Other Professional Activities
Editorial Advisory Board Appointments
Journal of Pharmaceutical Sciences (2003 – present)
Drug Development and Industrial Pharmacy (2005- present)
Current Drug Discovery Technologies (2007-present)
